
    
      This is a Phase 2, randomized, double-blind, parallel-group, multicenter, outpatient study
      evaluating the efficacy and safety of SEP 225289 in adults with ADHD using 2 oral dosages (4
      or 8 mg SEP 225289 once daily [QD]) versus placebo over a 4 week treatment period.
    
  